As of 2026-05-23, the Fair Value of CRISPR Therapeutics AG (CRSP) is -29.61 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 50.36 USD, the upside of CRISPR Therapeutics AG is -158.81%.
With the market price of 50.36 USD and our fair value calculation, CRISPR Therapeutics AG (CRSP) is not a good investment. Investing in CRSP stocks now will result in a potential loss of 158.81%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | 377.70 | -650.20 | -153.61 | -366.25 | -581.60 | -274.79 |
| YoY growth | 208.25% | -272.15% | 76.37% | -138.43% | -58.80% | -36.95% |
| Market Cap (mil) | 4,834.06 |
| P/E | |
| Forward P/E |
| EPS | -5.92 |
| Avg earnings growth rate | -36.95% |
| TTM earnings | -568.53 |